Clobetasol
| Evidence Level: L3 | Predicted Indications: 10 |
Table of Contents
Clobetasol: From Topical Corticosteroid Use to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Clobetasol is a super-potent topical corticosteroid, marketed in Singapore as scalp lotion, cream and ointment. The TxGNN model predicts it may be effective for primary cutaneous T-cell lymphoma (mainly early-stage mycosis fungoides). Support comes from 15 publications (including 3 observational cohort studies) and no registered clinical trials for this indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore license records |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.51% |
| Evidence Level | L3 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 3 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on known pharmacology, clobetasol is a super-potent topical glucocorticoid. Glucocorticoid receptor activation can induce apoptosis of malignant T cells and dampen local inflammatory and cytokine signalling in skin lesions.
This is a plausible mechanism for patch- and plaque-stage mycosis fungoides, the most common form of cutaneous T-cell lymphoma. Topical corticosteroids are already used in clinical practice for early-stage disease. In one large single-centre experience, topical clobetasol is described as first-line treatment for early-stage disease.
The support applies only to skin-directed control of early-stage disease. It does not extend to advanced, nodal or systemic lymphoma.
Clinical Trial Evidence
Currently no related clinical trials registered for primary cutaneous T-cell lymphoma.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14686970 | 2003 | Cohort | Dermatologic Therapy | About 200 patients with patch-stage mycosis fungoides treated with high-potency topical steroids; response rate over 90%, minor side effects; clobetasol is first-line at UCSF |
| 32603400 | 2020 | Cohort | Cutis | Observational study of skin adverse effects of clobetasol 0.05% cream in early-stage mycosis fungoides |
| 39741016 | 2025 | Cohort | Anais Brasileiros de Dermatologia | Compares clobetasol propionate with bexarotene in early-stage mycosis fungoides |
| 25027222 | 2014 | Case report | Ned Tijdschr Geneeskd | Child with hypopigmented mycosis fungoides successfully treated with clobetasol 0.05% ointment 4 days a week |
| 8987063 | 1996 | Case series | Pediatric Dermatology | Weekly pulse superpotent topical steroid in three children with lymphomatoid papulosis |
| 28031140 | 2016 | Case report | Skinmed | Angioimmunoblastic T-cell lymphoma initially misdiagnosed as psoriasis and treated with topical clobetasol; worsened |
| 36846176 | 2023 | Case report | Clinical Case Reports | Mycosis fungoides with psoriasiform plaques, initially misdiagnosed and treated with topical steroids |
| 23773745 | 2013 | Case report | Ann Dermatol Venereol | Papular mycosis fungoides case with literature review |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN09156P | CLODERM SCALP APPLICATION 0.05% | Lotion | Not stated |
| SIN10241P | CLODERM CREAM 0.05% w/w | Cream | Not stated |
| SIN09101P | CLODERM OINTMENT 0.05% | Ointment | Not stated |
All three licences are valid single-ingredient products from Hoe Pharmaceuticals Sdn Bhd.
Safety Considerations
- Drug Interactions: The interaction screen returned 100 records, none with a severity grade (all "Unknown"). Examples include other corticosteroids (prednisone, prednisolone, hydrocortisone, triamcinolone), proton pump inhibitors (omeprazole, pantoprazole, lansoprazole), and calcitriol and vitamin A.
- Literature safety signals: Prolonged use of potent topical clobetasol has been linked to skin adverse effects, and case reports describe iatrogenic Cushing syndrome from systemic absorption. Oral candidiasis has been reported in patients using topical corticosteroids. Because mycosis fungoides is a chronic disease needing prolonged treatment, these risks matter.
- Misdiagnosis risk: Several case reports show cutaneous lymphoma mistaken for psoriasis or eczema and treated with steroids alone, which can delay diagnosis.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: Evidence is limited to observational cohorts and case reports for skin-limited, early-stage mycosis fungoides, with no registered trials. The mechanism is plausible and topical clobetasol is already used in practice, but it supports only skin-directed therapy.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore Health Sciences Authority (HSA)
- Mechanism of action data from DrugBank
- Confirmation of the approved indications of the Singapore products
- Biopsy-confirmed diagnosis and specialist oversight, restricting use to early-stage, skin-limited disease
- A monitoring plan for skin atrophy, systemic absorption (HPA-axis suppression, Cushing syndrome) and secondary infection
- Prospective or controlled data comparing clobetasol with established topical options
Other Predicted Indications (Not Recommended at This Time)
| Predicted Indication | Score | Evidence Level | Decision | Comment | |------|------|------|------|------| | Lymphosarcoma | 98.88% | L4 | Hold | Outdated term for non-Hodgkin lymphoma; literature overlaps with cutaneous T-cell lymphoma and gives no support for systemic disease | | Crohn's colitis | 98.88% | L4 | Hold | Literature covers skin complications only and reports Cushing syndrome from topical clobetasol; no support for intestinal disease | | Disease of orbital region | 98.77% | L4 | Hold | Two completed Phase 3 trials (NCT04246801, NCT04249076) concern an ophthalmic clobetasol formulation for post-cataract-surgery inflammation; indication match unconfirmed | | Candidiasis | 98.60% | L4 | Hold | Candidiasis is an adverse effect of topical corticosteroids, a safety signal rather than a therapeutic one | | Cystic teratoma, spinal cord dermoid cyst, disease of orbital part of eye adnexa, dermoid cyst of ovary, polyp of vocal cord | 98.5–98.9% | L5 | Hold | No clinical or literature evidence and no plausible mechanism |
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.